BCR-ABL1 Kinase Domain Mutation Analysis IRMA
Understanding BCR-ABL1 Kinase Domain Mutation Analysis
The BCR-ABL1 Kinase Domain Mutation Analysis IRMA represents a cutting-edge diagnostic approach in molecular oncology, specifically designed to detect mutations within the kinase domain of the BCR-ABL1 fusion gene. This genetic abnormality is the hallmark of chronic myeloid leukemia (CML) and plays a pivotal role in disease progression and treatment response. The test employs sophisticated Sanger sequencing technology to identify specific nucleotide changes that may compromise the efficacy of targeted tyrosine kinase inhibitor therapies.
What This Test Measures and Detects
This comprehensive analysis specifically targets the kinase domain region of the BCR-ABL1 fusion gene, identifying:
- Point mutations affecting drug binding sites
- Amino acid substitutions that alter protein conformation
- Insertion and deletion mutations within critical domains
- Specific resistance mutations to imatinib and other TKIs
- Emerging mutations that may predict treatment failure
Who Should Consider BCR-ABL1 Mutation Testing
This specialized genetic analysis is recommended for patients experiencing:
- Suboptimal response to tyrosine kinase inhibitor therapy
- Loss of previously achieved molecular response
- Progressive disease despite ongoing treatment
- Planning for treatment modification or escalation
- Unexplained rising BCR-ABL1 transcript levels
Clinical Indications and Symptoms
Patients demonstrating clinical features such as persistent leukocytosis, splenomegaly, or hematological abnormalities despite TKI therapy should strongly consider this analysis. The test is particularly valuable for individuals who have failed to achieve expected milestones in their CML treatment journey.
Benefits of BCR-ABL1 Kinase Domain Analysis
- Personalized Treatment Planning: Identifies specific mutations to guide targeted therapy selection
- Early Detection of Resistance: Allows intervention before clinical progression occurs
- Optimized Therapeutic Strategies: Enables switching to alternative TKIs based on mutation profile
- Improved Prognostic Assessment: Provides valuable information for long-term disease management
- Cost-Effective Healthcare: Prevents unnecessary continuation of ineffective treatments
Understanding Your Test Results
Your BCR-ABL1 Kinase Domain Mutation Analysis results will provide detailed information about:
- Mutation Status: Presence or absence of specific kinase domain mutations
- Mutation Type: Identification of specific amino acid changes
- Clinical Significance: Interpretation of how detected mutations may affect treatment response
- Therapeutic Recommendations: Guidance on potential alternative treatment options
It’s essential to discuss your results with your hematologist or oncologist, who can provide personalized interpretation based on your complete clinical picture and treatment history.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | BCR-ABL1 Kinase Domain Mutation Analysis IRMA |
| Discount Price | $282 USD |
| Regular Price | $376 USD |
| Turnaround Time | 7-8 days |
| Sample Type | Bone marrow / Peripheral blood (Transport immediately) |
| Test Components | EDTA Vacutainer (2ml) |
| Methodology | Sanger Sequencing |
Pre-Test Instructions
The BCR-ABL1 Kinase Domain Mutation Analysis IRMA requires a physician’s prescription for testing. Please note that prescription requirements do not apply to surgical cases, pregnancy-related testing, or individuals planning international travel. Ensure proper sample collection and immediate transport to maintain sample integrity.
Nationwide Testing Availability
We proudly offer comprehensive genetic testing services across the United States, with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, and many other cities. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.
Take Control of Your CML Treatment Today
Don’t let treatment resistance compromise your leukemia management. The BCR-ABL1 Kinase Domain Mutation Analysis provides critical insights that can transform your therapeutic approach and improve long-term outcomes. Our experienced genetic counselors and hematology specialists are ready to assist you throughout the testing process.
Call us now at +1(267) 388-9828 to schedule your BCR-ABL1 mutation analysis or to speak with our genetic specialists about how this test can benefit your treatment journey.
Early detection of resistance mutations can make a significant difference in your CML management strategy. Book your test today and take the next step toward personalized, effective leukemia treatment.
